Skip to content
Menu

NeoGenomics, Inc. NEO

Full chart Compare
Set alert

Price alert · NEO

All alert types
15.25 USD -0.16 (-1.04%)

Regular-session close

15.25 0.00 0.00%

After hours · Nov 17, 4:26 PM ET

14.97 Day range 15.60
7.07 52-week range 20.15
YTD
+29.68%
1 year
+49.22%
Market cap
1.97B
Revenue (ttm)
787.75M
Profit margin
-4.10%
EPS (ttm)
-0.24
Shares out
129.39M
Forward P/E
48.48
YTD return
+29.68%
1-year return
+49.22%
50-day average
17.51
Volume
1.03M
Avg volume
1.98M
Open
15.60
Previous close
15.41
Day's range
14.97 – 15.60
52-week range
7.07 – 20.15
Beta
1.83
Price target
23.40 (+53.4%)
Earnings date
Feb 16, 2027

5D -1.56 (-9.19%)

1617TueWedThuFriMon15.41

Key statistics

200-day average
13.01
Enterprise value
2.30B
PEG ratio
2.09
Price / sales
2.50
Price / book
2.46
Revenue growth
11.40%
Free cash flow
4.80M
Total cash
139.28M
Total debt
449.14M
Return on equity
-3.94%
Short % of float
11.96%

Fundamental scorecard

7 of 25 checks passed on NEO’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
NEO Revenue — quarterly 209.25M
NEO Net income — quarterly -7.55M
NEO EPS — quarterly -0.06

Earnings

NEO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 16, 2027Dec 30, 20260.07———
Oct 28, 2026Sep 30, 20260.055460.07+0.01+26.22%
Jul 28, 2026Jun 30, 20260.033550.05+0.02+49.03%
Apr 28, 2026Mar 31, 20260.005780.010.00+73.01%
Feb 17, 2026Dec 31, 20250.040.06+0.02+50.00%
Oct 28, 2025Sep 30, 20250.020.03+0.01+50.00%

Upgrades / downgrades

NEO analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026TD CowenmainBuyBuy
Oct 29, 2026BTIGreitBuyBuy
Oct 6, 2026StoneXmainBuyBuy
Oct 6, 2026NeedhammainBuyBuy
Oct 6, 2026BTIGupNeutralBuy
Jul 29, 2026NeedhammainBuyBuy

About NeoGenomics, Inc.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States

News

Your note

Sign in to keep a note on NEO — it syncs with the Stock Master app.

Insider holders

NEO insider holders
InsiderRelationLatest transactionDateShares held
HANNAH ALISON L.DirectorConversion of Exercise of derivative securityMay 29, 2025131,023
HARRIS MELODYOfficerConversion of Exercise of derivative securityFeb 20, 2025109,755
KANOVSKY STEPHEN MICHAELDirectorConversion of Exercise of derivative securityMay 31, 202675,421
KELLY MICHAEL AARONDirectorConversion of Exercise of derivative securityMay 31, 202672,086
OLIVO ALICIA CGeneral CounselConversion of Exercise of derivative securityMay 10, 202693,567
SHERMAN JEFFREY SCOTTChief Financial OfficerConversion of Exercise of derivative securityFeb 22, 2026220,009

Institution ownership

NEO institution ownership
Holder% heldSharesValueReported
Blackrock Inc.15.53%20,091,857306.40MSep 29, 2026
First Light Asset Management, LLC6.54%8,459,556129.01MSep 29, 2026
Greenhouse Funds, LLLP6.49%8,395,422128.03MSep 29, 2026
Vanguard Portfolio Management LLC6.02%7,788,960118.78MSep 29, 2026
First Trust Advisors LP5.74%7,424,916113.23MSep 29, 2026
Vanguard Capital Management LLC4.44%5,744,06487.60MSep 29, 2026

Fund ownership

NEO fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.91%7,648,512116.64MSep 29, 2026
First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd.4.96%6,416,47497.85MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.20%4,136,53563.08MJun 29, 2026
Delaware Group Equity Funds V-Nomura Small Cap Core Fund3.15%4,081,05162.24MAug 30, 2026
iShares Trust-iShares Russell 2000 ETF2.60%3,359,51651.23MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.31%2,985,34845.53MJun 29, 2026